New name reflects the Company’s strategic evolution focused on later-stage preclinical assets leveraging its most advanced, signature gene-editing capabilities ...
Next-generation automation is closing the gap between curative science and real-world demand, enabling faster development, ...
Dad tells of anguish after daughter left in a wheelchair because the NHS in England and Wales doesn’t test for spinal ...
The first GMP cell therapy product ever manufactured for clinical use on the Cell Shuttle™ and released using Cell Q™, is expected to be infused into patients within Cabaletta’s RESET™ clinical trial ...
Potential blockbusters and root-cause treatments from Eli Lilly, Merck, Takeda and others could get a regulatory nod this ...
Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality ...
A new "double-pronged" CAR T immunotherapy recognizes two distinct features of multiple myeloma to destroy the cancer more ...
The UK National Screening Committee’s recent recommendation to introduce prostate cancer screening for men with faulty BRCA ...
At his highest, he weighed 540 pounds. This is how Jelly Roll went from preteen T-levels to Pink Panther energy and got lean.
CyPath® Lung addresses urgent unmet need in projected $10.4 billion lung cancer diagnostic market by 2034Precision Pathology Laboratory Services meets gold standard for excellence across all ...
Natera, Inc. , a global leader in cell-free DNA and precision medicine, today announced that new data from the ALTAIR trial will be presented at the 2026 American Society of Clinical Oncology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback